Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a credentialing agreement with managed care firm Prime Health Services to cover Rosetta's miRview mets2 test.

The deal is the first between Rosetta and a US preferred provider organization, Rosetta said. As a result, the number of covered lives having access to miRview mets2 as an in-network service totals more than 6.5 million.

The miRview mets2 assay is a microRNA-based assay for identifying the tumor of origin in cancers of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.